Arno Therapeutics, Inc. is a biopharmaceutical company, which focuses on the clinical development of targeted cancer therapies and novel drug candidates for unmet medical needs. The company is headquartered in Flemington, New Jersey. The company went IPO on 2008-06-11. The firm's product development pipeline includes Onapristone, AR-42, and AR-12 and analogs. Onapristone is indicated for endometrial, prostate and breast cancer indications. AR-42 is provided for hematological malignancies and solid tumors indications. AR-12 is offered for solid tumors and hematological malignancies, and various anti-microbial targets. Onapristone is a type 1 anti-progestin hormone blocker that has considerable anti-tumor activity in patients with breast cancer. The firm is engaged in developing and commercializing AR-42, which is an oral cancer therapy in early clinical development. AR-42 is a spectrum deacetylase inhibitor of both histone and non-histone proteins, which has potency and activity in solid tumors and hematological malignancies. AR-12 is an orally available cancer treatment.
Follow-Up Questions
Arno Therapeutics Inc (ARNI) の株価収益率はいくらですか？
Arno Therapeutics Inc の株価収益率は 0 です。
Arno Therapeutics Inc のCEOは誰ですか？
Dr. Alexander Zukiwski は Arno Therapeutics Inc の Chief Executive Officer で、2011 から在籍しています。
ARNI の株価パフォーマンスは？
ARNI の現在の価格は $0 で、最終取引日から 0% decreased 変動しました。
Arno Therapeutics Inc の主な事業テーマや業界は？
Arno Therapeutics Inc は Biotechnology 業界、セクターは Health Care に属しています。
